

# TereoPneuma

## **FOR IMMEDIATE RELEASE**

Tuesday, August 20, 2013

### **TereoPneuma Incorporates in California**

SAN DIEGO, CA August 20, 2013 - TereoPneuma, Inc., a CA based company developing the ReDe Mask™, today announced it has incorporated as a C corporation in the state of California.

TereoPneuma's founders are William J. Mazzei, MD and Warren G. Young, PhD. Dr. Mazzei is an anesthesiologist and Dr. Young is a neuroscientist. Both are serial entrepreneurs with strong backgrounds in the medical and scientific fields and together bring years of experience in developing and commercializing medical products.

As an internationally recognized expert in operating room management and medical device development, Dr. Mazzei will steer the company in cutting edge anesthesiology technology. Applying advanced technology such as imaging to the fields of quantitative neurobiology, Dr. Young is a renowned neuroscientist that has taken his discoveries to the commercial sector in drug discovery and advanced medical instrument development. Both Drs. Mazzei and Young have worked together in previous companies and form a synergistic team, nurturing their new ideas to the commercial phase in anesthesiology.

"TereoPneuma will serve as a springboard for many exciting products, the first of which will be the ReDe Mask™. We are also pleased to be work in San Diego, where the scientific, medical and engineering talent available here is without measure." said William J. Mazzei, MD, CEO of TereoPneuma, Inc.

### **About TereoPneuma**

TereoPneuma is a privately held medical device company in San Diego, CA whose mission is to develop novel high technology products in the field of anesthesia. TereoPneuma is Greek for "observe breathing". TereoPneuma's first product - the ReDe Mask™ - is a disposable, single use oxygen face mask and respiration monitor that simultaneously provides supplemental oxygen to patients while also detecting exhalation and displaying a visual signal of each exhalation. Further, it provides a visual warning signal when no breath is detected for 7.5 seconds, and a more vivid visual warning signal when no breath is detected for 20 seconds. Detailed information on the Company is available at [www.tereopneuma.com](http://www.tereopneuma.com).

### **Contact:**

William J. Mazzei, MD, CEO  
TereoPneuma, Inc.  
[info@tereopneuma.com](mailto:info@tereopneuma.com)